Liu, J. F., Barry, W. T., Wenham, R. M., Wahner Hendrickson, A. E., Armstrong, D. K., Chan, N., … Matulonis, U. A. (2018). A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca). In Journal of Clinical Oncology (Vol. 36, pp. 5519–5519). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.5519

Liu, Joyce F., William Thomas Barry, Robert Michael Wenham, Andrea Elisabeth Wahner Hendrickson, Deborah Kay Armstrong, Nancy Chan, David E. Cohn, et al. “A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).” In Journal of Clinical Oncology, 36:5519–5519. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5519.

Liu JF, Barry WT, Wenham RM, Wahner Hendrickson AE, Armstrong DK, Chan N, et al. A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5519–5519.

Liu, Joyce F., et al. “A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 5519–5519. Crossref, doi:10.1200/jco.2018.36.15_suppl.5519.

Liu JF, Barry WT, Wenham RM, Wahner Hendrickson AE, Armstrong DK, Chan N, Cohn DE, Lee J-M, Penson RT, Cristea MC, Abbruzzese JL, MATSUO K, Olawaiye A, Farooq S, Swisher EM, Van Allen EM, Shapiro G, Kohn EC, Ivy SP, Matulonis UA. A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5519–5519.